Home


Shaan Katari Libby
Founder / Director

Consultancy work
Grant-writing
Business development
Discussion fora
Topical seminars

Most recent seminar (20th April 2007):

“European Biotechnology”

Seminar on Friday 20th April 2007
9.30am – 1pm (Including lunch)
Magdalen Centre, Oxford Science Park

Speakers from Europe and the UK discussed their
companies and provided a first-hand account of the
life sciences environment in Europe today. A
regulatory overview was included, and there was
time for a discussion.

Speakers from:
Frank B. Dehn & Co.(UK)
Manches LLP (UK)
Pfizer (UK)
Pharma & Biotech Management Consulting (Italy)
ProBioGen (Germany)
SynCo Bio Partners (The Netherlands)

Fee to attend:
£35.00 for organisations of 5 or less persons
£35.00 for University representatives
£50.00 for all others
(VAT extra)

No cancellations or refunds are issued once
registered. You may send a substitute from the same
organisation.

Time:
9.30am Registration / Tea - Coffee
10.00am Seminar
12 noon Panel Discussion and Q&A
Networking Lunch

With thanks to our silver sponsors:
Frank B. Dehn & Co. and
Manches LLP

Speaker profiles available:
(this portion will be updated every couple of days)

Paolo Barbanti, Ph.D. MBA
Dr.Eliot R. Forster
Dr.Henning von Horsten
Joanne McCudden, Ph.D.
Dr. Philip M. Webber
Jim Kinnier Wilson

Paolo Barbanti, Ph.D. MBA

Paolo Barbanti began his career in biotechnology as
a researcher focusing on experimental cancer
therapies and completed his postgraduate studies in
the field of immunology and cell biology studying
the activity of various monoclonal antibodies in
oncology. He also received an MBA from SDA
Bocconi, School of Management. With his
background, in both the scientific and business
aspects of life sciences, he served as management
consultant for biotech and pharmaceutical
companies covering all aspects of their business.

Through his involvement with biotech start-ups,
multinational pharmaceutical companies, university
labs and merchant banks, Mr. Barbanti has
accumulated experience in technology assessment
transfering discovery into clinic, in product
management and launch of new pharmaceutical
products raising venture investment and
establishing strategic partnerships between
companies: biotech/biotech and biotech/pharma.

For research providers, including universities,
government labs, Mr. Barbanti helps build the skills
for effective generation, screening, selection and
development of new ideas, value projects and
technologies, providing guidance and help to
develop the necessary culture and competencies
within the organisation. He is also adjunct Professor
at University of Bari and Siena, School of
Biotechnology and lecturer at SDA Bocconi School
of Management besides at various courses and
seminars.

He is member of several professional associations:
LES (Licensing Executives Society), SIICA (Italian
Society of Immunology and Clinical Allergology) and
SSFA (Society for Applied Pharmacological
Sciences).

Dr.Eliot R. Forster

VP, Site Head of Development and Head of
Development Operations Eu and Asia, Pfizer

Eliot was born in the North East of England and has
lived and worked in both the UK and USA.

He is a graduate from the University of Liverpool,
where he gained a BSc and Ph.D. in
Neurophysiology and has an MBA from Henley
Management College.

Eliot has worked at both Glaxo and Pfizer across a
broad range of functions in the pharmaceutical
Development arena. Currently Eliot has the role of
VP, Site Head of Development and Head of
Development Operations Eu and Asia for Pfizer.
Eliot is a board director of a health consortium
under the SEEDA umbrella. He also works with
universities in support of their Enterprise activities.

Eliot has 3 children, active interests in politics,
running, food and wine.

Dr.Henning von Horsten

Dr.Henning von Horsten is the Marketing Manager in
the Business Development Department at ProBioGen
AG where he is responsible for customer relations,
acquisition, project management and project
coordination.

Prior to joining ProBioGen he was a Research
Associate in the Department of Cell Biology and
Biochemistry at Texas Tech University Health
Sciences Center, U.S.A. where he was responsible
for a protein characterization project funded by the
NIH.

After completion of an undergraduate degree in
Chemistry and Biology at the University of Kiel, he
received a Ph.D. in Molecular Biology from the
University of Hamburg for his research conducted at
the Institute for Hormone and Fertility Research
GmbH. During this time I was supported by a
graduate stipend from the Ernst Schering Research
Foundation.

ProBioGen is a specialist in mammalian producer
cell line development and contract manufacturing of
therapeutic proteins. ProBioGen covers the entire
service portfolio ranging from expression vector
construction, producer cell line development and
GMP manufacturing of biopharmaceuticals.

ProBioGen has long standing experience in setting
up cost effective manufacturing processes for single
chain proteins such as cytokines, enzymes, growth
hormones and recombinant fusion proteins as well
as for multi chain proteins such as monoclonal
antibodies.

Generating high performance producer cell lines for
monoclonal antibodies is far from trivial and
requires careful vector design including adjustment
of promoters and leader sequences. Over the years,
ProBioGen has developed know-how and expertise
in this area. For monoclonal antibodies ProBioGen
has identified several novel superior leader
sequences and promoters which are ideally suited
to adjust and synchronize the expression of light
and heavy chains which is a prerequisite for
achieving optimal secretion as well as a maximum
titer and yield with mammalian producer cell lines.
ProBioGen`s starter cells have been preadjusted to
ADCF medium which enables us to rapidly identify
the high producer clones and reduce the project
timeline.

Being a specialist in vector construction and
mammalian producer cell line development
ProBioGen has been contracted by major
pharmaceutical companies for several cell line
development projects and has repeatedly earned
their business in this field.

What makes us an attractive choice for our
customers is our long standing experience in
developing high yielding producer cell lines as well
as our attractive business model. ProBioGen offers
cell line development on a fee for service basis,
which is a strong advantage for our clients in
respect to avoidance of royalty stacking down the
road. Moreover, we have an open source model for
consumables. All of the consumables that we use in
cell line development as well as in contract
manufacturing are available from an open source
which ensures that our customers will be able to
benefit from the market competition in that arena.

In conjunction with our state-of the-art up- and
downstream process development we can develop
robust and economical manufacturing processes
starting with no more than an electronic gene
sequence file. In process development we are able
to meet every specific need for each individual
therapeutic protein. Whether your protein needs to
be manufactured in a batch or a perfusion process -
ProBioGen has all the resources in place to support
your project properly.

In addition to our contract manufacturing and cell
line development services, our cell technology
portfolio also includes designer cell lines for
therapeutic protein and vaccine manufacturing.
Designer cell lines generated by ProBioGen include
a human neuronal cell line that supports correct
glycosylation of therapeutic proteins as well as an
avian cell line for use in safe and cost effective
vaccine manufacturing processes.
Ongoing development projects on complex cell
systems round off ProBioGen's profile as a cell
technology specialist. Currently, ProBioGen is far in
the development of an artificial human lymphnode
for immunogenicity testing as well as for the
generation of de novo fully human antibodies.  


Joanne McCudden, Ph.D.
Joanne is business development manager for SynCo
Bio Partners BV in the Netherlands.  With
responsibilities for global sales and marketing
activities, Joanne works with a number of clients
across the World and clearly observes the effect of
different funding strategies and their effect on small
to medium biotech companies.  Prior to SynCo,
Joanne was employed as European sales manager
for Lark Technologies and account manager for
Cobra Biomanufacturing.  At Cobra, her
responsibility was for the commercial project
management of key manufacturing programs.  Prior
to taking up business development roles, she
completed her PhD at the University of Warwick
where she studied protein transport systems in E.
coli and Bacillus subtilis.  

SynCo Bio Partners (www.syncobio.com) is a GMP
contract manufacturing organisation, located in the
Netherlands .  With over 14 years experience in the
manufacture of biopharmaceuticals for clinical trials
and The Market, SynCo is able to offer a fully
integrated range of services from process
development, production of bulk drug substance
and fill/finish, at all stages of product development
including commercial launch.

Dr. Philip M. Webber
European Patent Attorney, UK Chartered Patent
Attorney
Partner, Frank B. Dehn & Co. (Oxford and London)

Dr. Webber obtained his first degree from
Cambridge University, (Natural Sciences, Genetics)
and then carried out research on the regulation of
brain-specific genes at Warwick University, where
he obtained his PhD.  He qualified as a UK
Chartered Patent Attorney and European Patent
Attorney with Frank B. Dehn & Co. and is now a
partner in their Life Sciences Group.  

He has a worldwide client-base including clients
from the UK, Scandinavia, the US and Japan.
Amongst other things, his work involves the
preparation and filing of patent applications in
Europe and throughout the world; acting for his
clients in opposition procedures at the European
Patent Office; and searching for and advising his
clients on the relevance of competitors' patents.  He
is an active member of the Biotechnology Committee
of the UK Chartered Institute of Patent Attorneys.  He
has spoken at a number of European conferences
and on BBC Radio on the patenting of biotech
inventions, as well as publishing a number of
papers in this area.

Frank B. Dehn & Co. is one of the leading firms of
Patent and Trade Mark Attorneys in Europe, with
offices in Oxford, London, Brighton and Munich. It
has consistently been ranked by Legal 500 in the
top tier of Patent firms and is described in the
current edition of Legal 500 as being "world class"
and "right at the top of their game". Last year, they
were described as having an “outstanding
partnership”.

Frank B. Dehn & Co. has over 60 science graduates,
23 of whom also have PhDs. Its specialist patent
practice groups serve clients in all fields of
technology, including Chemistry and Biotechnology,
Engineering and Electronics. The firm provides a
full range of intellectual property services, including
advice and filing of patents, trade marks and
designs.

Frank B. Dehn & Co. act for a variety of clients
including universities in the UK and elsewhere,
SME's and larger companies. Their clients include
the Ares-Serono Group, Boehringer Ingelheim
GmbH, Borealis A/S, ConocoPhilips, EI Du Pont de
Nemours & Company, GSK, Honda Motor Co., Ltd.,
Kimberly-Clark Corporation and Medtronic, Inc.  


Jim Kinnier Wilson
Technology / Intellectual Property Partner
Oxford Office, Manches LLP

Jim graduated in biochemistry from the University of
Aberdeen, and progressed to an MSc in biochemical
engineering from the University of Birmingham
before converting to law. He was articled at the
niche intellectual property firm, Bristows Cooke &
Carpmael. He spent 5 years with City law firm
McKenna & Co, before joining NabarroNathanson in
October 1993. He joined Manches from Nabarros in
May 2003, as a Partner in the Technology & Media
Department in the Thames Valley office.
Jim has specialised in intellectual property since
admisssion in 1987, conducting disputes relating to
patents, copyrights, trade marks, confidential
information and designs.

With his technical background he has also advised
a number of science and engineering based clients
on the protection and exploitation of their IP rights
through R&D agreements, licensing, sales and
acquisitions, especially for clients in the
pharmaceutical, biotechnology, agri-bio, medical
device and veterinary medicines sector. His clients
range from academics and university technology
transfer offices, through growing companies to
those listed on the London and New York stock
exchanges.

Jim's varied litigation experience includes over 30
patent matters taken or defended at court and in the
Court of Appeal including the leading cases:
Patents: Coin Controls v Suzo
Copyright: Reject Shop v. Manners
Trademarks: Gallup v Gallup International
Association and Ors

Jim is a member of the Licensing Executives
Society, is an Associate of the Chartered Institute of
Patent Agents, and is a member of the European
Patent Litigators Association. Jim is also an
accredited mediator of ADR Group.
Formerly a keen off-shore sailor, Jim completed a
circumnavigation in 1993. Married with 2 young
children and living about as far from the sea as is
possible in the UK, leaves little time for sailing these
days.

   


Previous seminars:

“Protein Optimisation – Seminar & Discussion”

Friday December 8th 2006

10am – 1pm
(including a lunch buffet)
Oxford Science Park

This seminar and discussion provided broad
information about the objectives of protein
engineering covering the two main markets:
therapeutic proteins and industrial enzymes. The
technical options were discussed, from rational
design to directed evolution, and finally the
approach followed by Proteus and others joining the
discussion with some examples.

The guest speaker made a formal presentation,
followed by an opportunity for attendees to
participate by speaking for 2-3 minutes each about
their own areas of expertise and what they wished
to discuss or hear more about.

An informal networking lunch followed.

Speaker:

Ingrid Marchal-Gerez, Ph.D.
Business Development Manager, Northern Europe
PSI - Proteus Services for Industry
France
www.proteus.fr

Organiser: Shaan Libby
Shaan Libby & Associates

Feedback from the recent seminar on Microfluidics
(Sep 06):
Oxford Science Park

"The seminar was very useful."
- Sameer Kothari, CEO, Plasso Technology Ltd.
(Sheffield)

"I think organising this conference was a great idea.
Not only were the talks interesting, the event itself
was actually *useful*. The fact that it was a rather
small audience made it perfect for networking
purposes. I hope you will organise more of these
events in the future."
-Dr Wouter Meuleman, Project Manger,
Oxford Gene Technology (Oxford)

"It was a great networking opportunity, and nicely
presented!"
-Dr Mark Reeves,MRA Technology Ltd (Oxford)

Interested to be one of the sponsors of a future
seminar? Please contact Shaan@shaanlibby.com.

Recent seminar:
Please get in touch if you would like a summary and
copies of non-confidential presentations. A fee
applies.

“Microfludics, Detection Technologies, and
Biodefence”

Date held: September 20th 2006 (Wednesday)
10.00am - 12noon (followed by a lunch buffet)
Oxford Science Park

This seminar discussed biological sample
processing and detection technologies and
reviewed relevant academic work, and the
development of technologies which will enable a
new generation of ultra-sensitive multiplex
diagnostic tools for the clinical diagnostic and life
science markets. The role played by such tools in
the important area of biodefence in the US and UK
was also discussed, rounding off with a discussion
of where we see this area heading in the future.

Speakers:

David Browning – CEO Healthcare at Oxonica

M. Allen Northrup Ph.D. (Chief Technology Officer)
Microfluidics Inc. (California-based company)

Dr. Mark Tracey (Reader in Microfluidics)
Science and Technology Research Institute,
University of Hertfordshire

Moderator: Shaan Libby (Founder)
Shaan Libby & Associates

Fee to attend:
£20.00 for organisations with 5 or less employees
£20.00 for University representatives
£40.00 for all others

To register: E-mail shaan@shaanlibby.com  
or Phone: 07932 394 232

Speaker profiles:

David Browning, MSc FIBMS FCIM is Business
Director of
Oxonica Healthcare.

David brings more than 20 years of applied
healthcare
experience to Oxonica’s management team.
Graduating in
Biochemistry, with post graduate qualifications in
Biochemical
Immunology and Marketing, David’s career has
encompassed
roles from diagnostics research to customer sales
and support
and business management.

His experience has been gained within a wide range
of
organizations and companies including the UK
National Health
Service, Amersham plc, Johnson & Johnson Clinical
Diagnostics and IGEN International, Inc.

David’s principle focus has been on expediting the
development and international commercialisation of
advanced
clinical diagnostics products within healthcare and
related fields.
His role within Oxonica is to drive the development
and
commercialization of Oxonica’s highly innovative
nanotechnology-based product portfolio within the
clinical
diagnostics and UV-protection fields.

M. Allen Northrup, Ph.D.

Dr. M. Allen Northrup is a co- founder of Microfluidic
Systems Inc (MFSI) and is the President and CEO.
MFSI is
focused on the development and manufacturing of
automated
pathogen and human DNA processing and detection
systems
using microfluidics technologies.

From 1997-2001, Dr. Northrup was a co-founder,
Chief
Technical Officer, and Vice President of Research at
Cepheid,
in Sunnyvale, CA.  He has over 25 years of
instrumentation
development experience.  Dr. Northrup’s technical
interests
center on the application of  microfabrication and
related
technologies to the development of environmental,
medical,
and biotechnological devices and instruments -
specifically to
take advantage of the increases of efficacy and
decreases in
costs these technologies can offer. Dr. Northrup was
the first
to demonstrate the micro-PCR process in a silicon
micromachined chip and has worked closely with
many
companies in the biomedical industry over the past
several
years to prove its advantages and to move it toward
commercialization.

While at Cepheid he initiated and was the Principal
Investigator  of numerous DoD Grants, and Research
and
Development projects from DARPA, USAMRIID,
LLNL, and
SBCCOM. These projects involved the development
of
microfluidic bioassay sample processing and
analysis systems.
Prior to his Ph.D., Dr. Northrup worked for six years
in the
analytical instrument industry (Finnigan MAT),
specifically in the
areas of gas chromatograph/mass spectrometer
instrument
reliability, engineering, manufacturing, and
technical marketing.
Dr. Northrup received his Ph.D. in Biomedical
Engineering
from the University of California at Davis. In his Ph.D.

research, conducted at Lawrence Livermore National
Laboratory (LLNL), he developed several analytical
instruments including fiber optic biosensors and
micro-
fluorescence imaging systems.

He was awarded a DOE Graduate Fellowship and
was later
offered a National Research Council Postdoctoral
(NRC)
Fellowship.
From 1991-1997, Dr. Northrup was a post-Doctoral
Fellow,
Research Scientist, and finally a  Principal Engineer
at
Lawrence Livermore National Laboratory (LLNL). His
last
LLNL position was in the Microtechnology Center of
the
Engineering Research Division.  Dr. Northrup was a
Visiting
Scholar at the University of California at Berkeley
from 1991-
96 and an Adjunct Assistant Professor in the
Department of
Radiology at the University of California at San
Francisco
Medical Center from 1996-99. Dr. Northrup was, most
recently,
a Consulting Professor in the Center for Integrated
Systems,
Department of Electrical Engineering, Stanford
University. Dr.
Northrup has over 40 publications, 35 issued
patents, and
numerous others pending.

He serves on a variety of committees and review
panels. This
includes being appointed to National Academy of
Sciences
(NAS)/Research Council (NRC) Committee on the
Future of
Biotechnology for the Army (1999-present) and the
Policy
Board of the DARPA Center for Biochemical
Optoelectronic
Microsystems (CBOM), involving Harvard, University
of
Rochester, and Cornell Universities. He has been a
steering
committee member, invited speaker, and conference
chairman
at many conferences in the US, Asia, and Europe.
He  was the
Chairman of Total Micro Analysis (µTAS) conference
in Oct.
2003 and is on the Board of Directors of the
Chemical and
Biological Microsystems Society.  Dr. Northrup is on
the
Editorial Board of Biomedical MicroDevices and
continues to
be a reviewer on several scientific and engineering
journals.


MicroFluidic Systems Inc. (MfSI), a privately held
corporation,
was founded in 2000 with the goals of continuing
the work of
its founders; that is developing microfluidics-based
automated
biological sample processing and detection. Since
its
inception, MfSI has raised over $40 million USD in
development contracts from both private and US
Government
sources, including the Departments of Defense and
Homeland
Security. Currently, MfSI occupies about 20,000 sqft
in office
and R and D facilities, including Biosafety Level 2
laboratories
in Fremont, California, and has about 15 employees,
including
3 PhD level engineers and scientists. Using
development
contracts for the development of automated
pathogen and
human DNA processing and detection systems for
biosecurity
and forensics applications, MfSI is concurrently
developing
commercial products for use in diagnostics,
environmental
monitoring, food and beverage testing, and
biotechnology.
www.mfsi.biz


Dr. Mark Tracey

Title of talk:
A Simple Solid-phase Suspension Compatible
Micropump Technology for
Real-world Samples.

Mark Tracey is Reader in Microfluidics at the
University of Hertfordshire's Science and
Technology Research Institute in Hatfield. He heads
the Microfluidics Research Group which conducts
both academic research and applied contract
instrument development. The group is relatively self
contained and multi-skilled allowing it to conduct
'turn-key' prototype system research, design and
development for external agencies based upon their
own, or UH designed and (depending upon the
requirement)fabricated, microfluidics. Commercial
experience has included biothreat detection
developments.

By training Mark is an electronics engineer. Prior to
becoming an academic he worked in industrial
research (STL Harlow, Sinclair Research
Cambridge). He has worked in microfluidics for the
last 15 years. His current interests lie in
multidisciplinary applications combining rapidly-
prototyped microfluidics with digital and analogue
electronics, optics, acoustics and other techniques
to yield novel solutions in the biosciences. Current
public domain research includes techniques for
micropumping, as discussed in this presentation,
particle and cell sorting, microdosing and stem cell
culture.

Previous seminars:

'Global Biotech: Spotlight on Australia'
Thursday 31st August 2006
Oxford Science Park
9.30am -12.00noon
Lunch buffet followed

Speakers:

- Helen Ujvary
Ferghana Partners (Australia-based Associate)

- Nigel Whittle PhD MBA
International Technology Promoter - Australasia
DTI Global Watch Service

- Dr.Fintan Walton
CEO, Pharma Ventures

Moderator: Shaan Libby
(Founder, Shaan Libby & Associates)

The seminar involved a discussion of Australian life
sciences as a whole, along with some emphasis on
the following new technology companies. It also
described how the British and Australian
Governments seek to help you collaborate with this
exciting growing market. There was then an
opporutnity to meet these Australia contacts after
the seminar over lunch.

GroPep develops novel factors that increase cell
growth, as well as manufactures and commercialises
them globally in three sectors of the pharmaceutical
industry: (a) as biopharmaceuticals to treat human
disease (b) as key agents that support the growth of
cell types engineered by pharmaceutical companies
for the large scale manufacture of new-generation
biopharmaceuticals; and (c) as reagents for
researchers to evaluate new medical concepts.
Bresagen Ltd

BresaGen is a South Australian biotechnology
company committed to the commercial development
of protein and peptide therapeutics. BresaGen
supplies biopharmaceutical API products as well as
material for clinical trials. The Company is listed
and quoted on the ASX.

Bionomics Ltd
Bionomics Limited is a biotechnology company
creating differentiated, small-molecule drugs to
serve large unmet needs in cancer and disorders of
the central nervous system. The company has
grown rapidly since its founding in 1999, and is now
Australia’s first fully integrated drug discovery
company. Bionomics has proprietary platforms in
target identification, high throughput screening,
medicinal chemistry, and preclinical development.
Using its CNS technologies, Bionomics became the
first company in the world to develop a genetic test
for Severe Myoclonic Epilepsy of Infants.


'BIOLOGICAL HAZARDS & EMERGENCY PLANNING'
9.30am – 11.30am   Friday April 28th 2006
Magdalen Centre, Oxford Science Park

Click here to download Shaan Libby's presentation
about the
U.S.Biodefence sector.

The other speakers' presentations had some
confidential information included, so cannot be
made available on the web.

Sponsors:
Bronze - Biotech International
Silver - Mathys & Squire (Patent & Trademark
Attorneys)
Gold - Frank B Dehn & Co. (Patent & Trademark
Attorneys)

A seminar providing a scientific overview of H5N1
and other dangerous pathogens, along with the
resulting commercial implications.

Speakers:

Dr. David Rhodes, (Head of Business Development,
Health Protection Agency) will provide a scientific
overview of the deadly pathogens causing Avian flu,
West Nile Virus, SARS, and vCJD and current
emergency planning in case of a pandemic.

Dr.Charles Potter (Chief Executive Officer, Caretek
Medical Ltd.) will illustrate the urgency of treatment
during pandemics or situations of
bio-warfare. There is tremendous commercial
potential for the right applications, and some of
these will be discussed.

Shaan Libby (Founder, Shaan Libby & Associates)
will moderate the seminar and provide an overview
of the US biodefence sector and details of some
commercial partnership opportunities that exist at
present.

Background on the organizations involved:

The Health Protection Agency The Health Protection
Agency's role is to provide an integrated approach
to protecting UK public health through the provision
of support and advice to the NHS, local authorities,
emergency services, other Arms Length Bodies, the
Department of Health and the Devolved
Administrations. The Agency was established as a
special health authority (SpHA) in 2003.

Caretek Medical Ltd. Caretek Medical Ltd has
developed a needle-free, transdermal drug delivery  
technology ImplaJect® - that pushes a
pharmaceutical formulation in a solid, semi-solid or
liquid form directly through the skin of a human or
animal using the needleless, spring powered,
ImplaJect® device. ImplaJect® could provide a user-
friendly and cost-effective alternative method to
deliver many protein-based drugs in solid form.  
They are in the process of co-developing the
technology for both generic and proprietary
medicines.

Fee to attend:
£40.00 for service providers
£10.00 for companies / universities

To register:
Please click here or e-mail shaan@shaanlibby.com
with your contact details. You should receive a
prompt e-mailed confirmation.

24th February 2006
'‘Funding for Biotech/Healthcare: A panel discussion’
Oxford Science Park
9.30am-12noon

Attendees heard about the various funding options
on offer to young biotech / medical device
companies, and when they should look to these.
Discussions took place in an open forum.
Panelists:
Julie Crane (Finance South East Limited)
Dr.Matthew Frohn (Oxford Venture Capital Trust)
Tara Lambert (SEEDA)
James Mallinson (Isis Innovation Ltd.)

Moderator: Shaan Libby
Fee: £30.00 service providers; £15.00 all others

20th January 2006
'An insight into SROne - GSK's venture arm'
Guest Speaker: Dr.Deborah Harland, Principal,
SROne
Oxford Science Park (10am-1pm)


'An Insight into Genentech: the world's second
largest biotechnology company'
5th October 2005
Guest Speaker: Dr. Jonathan Lewis (Associate
Director for Business Development at Genentech,
California)

My team of independent professionals and I have
expertise in the fields of Biotechnology,
Pharmaceuticals, Medical Devices, and
Environmental Technology.  

The ways in which we can help you are through a
variety of different services.  These can be divided
into two broad categories:
1. Strategic Consulting, and
2. Networking services

1. Strategic Consulting

At Shaan Libby & Associates, we have a team of
highly qualified associates, all available on a project
basis to help you understand the market, the
competition, and the likelihood of success.  You will
receive our assessment of how best to approach the
market and your best strategy going forward.

Read more about the team.

2. Networking services

The success of most businesses relies heavily on
visibility and the strength of the contact base or
network.  Here at Shaan Libby & Associates we have
a strong network in the UK, the US, and in India.  We
are willing to develop other markets if requested.  

You may not have the time to devote to getting in to
see the right people, whether this be for business
development purposes, marketing, regulatory
advice, executive recruitment, access to venture
capital, or Government grants.  Allow us to do the
legwork for you, maximizing both time and
efficiency, and we can put you in touch with the
right people in order to help you grow.

Read more about the service offerings.


Thank you for visiting our site, and please contact
us for any further information.


Speaker profiles:

Dr Nigel Whittle

Nigel has over 20 years experience of working in the
biotechnology industry, in scientific, commercial
and managerial roles.  He graduated from Oxford
University with a degree in Biochemistry, and went
on to complete a PhD in groundbreaking cancer
research at the ICRF Laboratories in London.  After a
short spell at Genentech Inc in the US, he joined
Celltech as a founder member of the antibody-
engineering group, and later joined Cantab
Pharmaceuticals to head the Molecular Immunology
Group, developing novel antibodies,
immunomodulators and therapeutic vaccines.  Later,
as VP of Project Management, he was responsible
for overall company project development, taking a
number of products into Phase II clinical trials.  

He helped to implement the successful merger with
Xenova, then left to study for an MBA at the Judge
Business School at Cambridge University.  
Subsequently he joined PA Consulting Group, where
he worked with a range of companies, from small
biotechs to large international pharma companies,
providing business support for licensing, product
valuation, due diligence and strategy development.  
He was recruited by IP2IPO to drive the programme
of technology commercialisation from Kings College
London, and represented IP2IPO on the Boards of 3
life-science start-ups.  He is currently a director of
Proximagen Neurosciences, which floated on AIM in
March 2005, raising over £13 million to progress its
development programme.

Nigel has recently accepted a position within the DTI
as an International Technology Promoter to identify
and facilitate the transfer of innovative technology
and knowledge into UK companies.

Shaan  Libby  &  Associates